NCT03874897: Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Study Summary

An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.

Interventions

CAR-CLDN18.2 T-CellsDRUG

Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2

PD-1 Monoclonal AntibodyDRUG

Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1

ChemotherapyDRUG

First-line systemic therapy according to physician's choice

Study Locations

Facility	City	State	Country
Department of GI Oncology, Peking University Cancer Hospital	Beijing	Beijing Municipality	China
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	China
The First Affiliated Hospital , Zhejiang University School of Medicine	Hangzhou	Zhejiang	China

Official Trial Information

View on ClinicalTrials.gov

An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects

Study Summary

Interventions

Study Locations

Official Trial Information